GSK caps U.S. out-of-pocket costs at $35/month for portfolio of COPD inhalers

GSK announced it will cap out-of-pocket costs for eligible patients at no more than $35 per month for all of its asthma and chronic obstructive pulmonary disease medicines, the most prescribed portfolio of inhalers in the U.S. GSK is taking this action as part of its longstanding commitment to improving access to respiratory medicines in the U.S. and to help asthma and COPD patients who are least able to afford the care they need. The out-of-pocket price cap will provide a significant benefit to patients taking these medicines whose monthly costs currently exceed $35.00. The program is wide reaching and will be implemented no later than January 1, 2025.